Sulpiride and tardive dyskinesia

Sulpiride in tardive dyskinesia.

The abnormal involuntary movements in tardive dyskinesia can be reduced by the dopamine antagonist drugs, phenothiazines and butyrophenones, but most cause an increase in Parkinsonian signs. Sulpiride, a benzamide derivative, and selective antagonist of D2 receptors had a significantly beneficial effect on most of 15 patients (p less than 0.01). In 12 patients the improvement was marked. The re...

A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia.

Eleven patients with Huntington's disease and nine patients with tardive dyskinesia participated in a randomised double-blind crossover trial of sulpiride (as sole antidopaminergic therapy) versus placebo. Although functional improvement was not seen in Huntington's disease patients, sulpiride reduced movement count and total dyskinesia score in both conditions. Sulpiride differs pharmacologica...

Metoclopramide and tardive dyskinesia.

Metoclopramide (MCP) is a D-2 receptor blocker (Kebabian and Calne 1979), which has been available by prescription in the United States since 1979 for use as an antiemetic in a wide range of situations. One of the common indications for MCP is the &eatment of diabetic gastroparesis (Physicians' Desk Reference 1993). A few recent reports suggest that diabetes mellitus may be a risk factor for ta...

Tardive dyskinesia and dementia.

Seventeen schizophrenic patients with tardive dyskinesia (TD) and 33 schizophrenics without tardive dyskinesia were examined by psychological tests of intellectual function and EMI scans were performed. The group as a whole were found to be demented and 31 out of 45 had abnormalities on the scan. On a learning test the tardive dyskinesia group did significantly worse and using a measured parame...

Clozapine-induced Tardive Dyskinesia